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Abstract
Objective: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC
patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment
will be beneficial to improve the treatment of HER2-positive BC patients. In this study, we identified trastuzumab-responsive
microRNAs that are involved in the therapeutic effects of trastuzumab.
Methods and Results: RNA samples were obtained from HER2-positive (SKBR3 and BT474) and HER2-negetive (MCF7 and
MDA-MB-231) cells with and without trastuzumab treatment for 6 days. Next, we conducted a microRNA profiling analysis
using these samples to screen those microRNAs that were up- or down-regulated only in HER2-positive cells. This analysis
identified miR-26a and miR-30b as trastuzumab-inducible microRNAs. Transfecting miR-26a and miR-30b induced cell
growth suppression in the BC cells by 40% and 32%, respectively. A cell cycle analysis showed that these microRNAs
induced G1 arrest in HER2-positive BC cells as trastuzumab did. An Annexin-V assay revealed that miR-26a but not miR-30b
induced apoptosis in HER2-positive BC cells. Using the prediction algorithms for microRNA targets, we identified cyclin E2
(CCNE2) as a target gene of miR-30b. A luciferase-based reporter assay demonstrated that miR-30b post-transcriptionally
reduced 27% (p=0.005) of the gene expression by interacting with two binding sites in the 39-UTR of CCNE2.
Conclusion: In BC cells, trastuzumab modulated the expression of a subset of microRNAs, including miR-26a and miR-30b.
The upregulation of miR-30b by trastuzumab may play a biological role in trastuzumab-induced cell growth inhibition by
targeting CCNE2.
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Introduction
The overexpression of HER2 has been reported in 20% to 30%
of patients with breast cancer. The overall survival and time to
relapse for patients whose tumors overexpressed HER2 were
significantly shorter [1,2]. The malignant phenotypes are also
enhanced with HER2 overexpression. HER2-overexpressing
tumors are also more likely to be resistant to treatment with
tamoxifen and standard chemotherapy [3–5].
Trastuzumab (Herceptin) was designed to target the extra-
cellular domain of HER2 and block its function, and is currently
used in patients with HER2-positive breast and gastric cancers.
The application of trastuzumab in the adjuvant and metastatic
setting has been shown to prolong the survival of patients with
HER2-positive breast cancer [6,7]. The overall response rate was
approximately 26–31% for trastuzumab monotherapy [8,9], and
50–61% for trastuzumab-chemo combined regimens [6,7].
Moreover, most patients with an initial response developed
resistance to trastuzumab within one year [10]. Therefore,
clarifying the molecular mechanisms of trastuzumab treatment
will be beneficial to improve the treatment of HER2-positive
breast cancer. For example, more fundamental knowledge about
the mechanisms responsible for trastuzumab treatment would
helpful in developing a monogram for tailoring trastuzumab
treatment, and a novel agent for modulating the trastuzumab
sensitivity of breast cancer cells.
According to accumulating reports, trastuzumab is thought to
induce its therapeutic effects basically via two biological mecha-
nisms: a direct effect by a blockade of the HER2 signal, and an
induction of antibody-dependent cell-mediated cytotoxicity
(ADCC). In terms of the direct therapeutic effects, trastuzumab
binds to the extracellular domain of the HER2 molecule, and
represses the signal transduction from the HER2 molecule by
inhibiting the homo/hetero dimerization of HER2 and HER
family members. Moreover, trastuzumab reduces the amount of
HER2 on the breast cancer cell surface by promoting the
internalization and cleavage of HER2 molecules. Therefore,
trastuzumab blocks the downstream signal pathways from HER2
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pathways. However, little is known regarding the biological role of
microRNAs in the trastuzumab therapeutic mechanism.
MiRNAs are a class of short, non-coding RNAs 18–25
nucleotides (nt) in length that are found in animal and plant cells.
In 1993, the first miRNAs were recognized in C. elegans. In 2001,
various small regulatory RNAs were discovered in plants and
mammals, and were designated as ‘‘microRNA’’s. As of today,
1921 human miRNAs are registered in the miRBASE database
(Release 18, November, 2011). MiRNAs are involved in RNA
interference (RNAi) machinery to regulate gene expression post-
transcriptionally, and contribute to diverse physiological and
pathophysiological functions, among them the regulation of
developmental timing and pattern formation, the restriction of
differentiation potential, cell signaling, and carcinogenesis.
In the present study, we screened for trastuzumab responsive
microRNAs by utilizing microarray-based microRNA profiling.
We identified miR-26a and miR-30b, which were induced in
breast cancer cells by trastuzumab exposure, and played important
biological roles in the trastuzumab therapeutic mechanism.
Materials and Methods
Cell lines and trastuzumab
Human mammary epithelial cells (HMEC, CC-2551, Lonza)
were cultured using the medium supplied by the MEGM Bullet
Kit (CC-3150, Lonza) at 37uC and 5% CO2. In this study, we used
a total of 11 breast cancer cell lines. Among them, MCF7,
MDAMB231,SKBR3, T47D (obtained from the American Type
Culture Collection, ATCC), MDAMB453 (RCB1192, RIKEN
BioResource Center), HMC-1-8, and MRK-nu-1 (JCRB0166 and
JCRB0628 respectively, Health Science Research Resources Bank)
were cultured in RPMI 1640 medium (Invitrogen) containing 10%
FBS. BT474 (HTB-20, ATCC) Hs578T (86082104, European
Collection of Cell Culture), YMB1E (TKG0440, Cell Resource
Center for Biomedical Research, Tohoku University, identical to
ZR-75-1,) were cultured in DMEM containing 10% FBS.
Trastuzumab was kindly provided by Chugai Pharmaceutical
Co., LTD. (Tokyo, Japan).
DNA and RNA extraction from cells
The genomic DNA of breast cancer and HMEC cells was
extracted using a DNeasy kit (Qiagen, Germany). Small RNA-
preserved total RNA samples were extracted by a combination of
Isogen reagent (Nippon Gene, Co., LTD. Japan) and a PureLink
RNA mini kit (Invitrogen). The amount of DNA and RNA was
measured by a Nanodrop spectrophotometer (ND-1), and the
RNA quality of the samples was assessed by an Agilent’s
Bioanalyzer system (model-2100 and RNA 6000 nano kit).
Assessment of HER2 amplification status in cell lines
The genome amplification status at the HER2 locus in HMEC
and the 11 breast cancer cell lines was assessed by quantitative
genomic PCR. The amount of amplification at the HER2 locus
was normalized by the average amount of NLK and ACACA
located between HER2 and the centromere of chromosome 17.
The genomic amount of the HER2 locus relative to that in the
HMEC cells represented the amount of HER2 amplification in the
cell lines. The sequence information used in this quantitative
genomic PCR is listed in Table S1.
Quantitative RT-PCR
The mRNA expression levels of genes such as HER2 in the cell
lines were assessed by SYBR green based quantitative RT-PCR
(SYBR Green PCR Master Mix, Applied Biosystems, Carlsbad,
CA). The RT-PCR data were normalized against the GAPDH
expression in the cells. The sequence information used in this
quantitative RT PCR was also listed in Table S1. The expression
levels of individual miRNAs were determined by an ABI 7300
Sequence Detector
TM (Applied Biosystems, Foster City, CA) with
TaqMan MicroRNA Assay kits for hsa-miR-26a and 30b (Applied
Biosystems). The miR-16 was used as an internal control to
normalize the microRNA expression levels [11].
MicroRNA expression profiling
To identify trastuzumab-inducible microRNAs, we performed
microRNA expression profiling using microRNA microarray
technology. The RNA samples were extracted from two HER2-
positive cell lines (SKBR3 andBT474) and two HER2-negative cell
lines (MCF7 and T47D), that were cultured with and without
trastuzumab (4 mg/ml) for 144 hours. The global microRNA
expression profiles of the 8 RNA samples were obtained using a
Toray’s microRNA microarray platform based on miRBase version
12 (3D-Gene miRNA oligo chip, Toray Industries Inc., Tokyo,
Japan), as previously described [12]. Briefly, for each patient,
500 ng of total RNA derived from both tumor and non-tumor
samples were labeled using a miRCURY LNA
TM microRNA
Power Labeling Kit Hy5 (Exiqon, Vedbaek, Denmark). The labeled
samples were individually hybridized onto the DNA chip surface,
and were incubated at 42uC for 16 hours. The washed and dried
DNA chip in an ozone-free environment was scanned using a
ProScanArray
TM microarray scanner (PerkinElmer Inc. Waltham,
MA). The obtained microarray images were then analyzed using
Genepix Pro
TM 4.0software(MolecularDevice, Sunnyvale, CA). In
this study, the median values of the foreground signal minus the
local background were calculated as the feature intensities.
Transfection
The cells were plated at a density of 2610
5 cells per well in a 6-
well format, or 5610
3 cells for a 96-well format 24 hours before
the transfection. The microRNA precursor oligos, microRNA
inhibitor, or negative control RNA (ncRNA) oligos (final
concentration: 25 nM for mimic oligo, 40 nM for microRNA
inhibitor) were transfected into cells using an X-tremeGENE
siRNA Transfection Reagent (Roche). The medium was replaced
eight hours after the transfection.
WST-1 assay
We utilized a WST-1 assay for assessing the sensitivity of the
cells to trastuzumab and the effect of the microRNA on cell
proliferation. Regarding the sensitivity of the cells to trastuzumab,
5000 breast cancer cells were plated per 96-well plate on Day 0.
From Day 1 to Day 6, the cells were exposed to trastuzumab at
different concentrations of 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16,
and 32 mg/ml, and the culture media containing trastuzumab
were replaced every 72 hours. On Day 6, 10 ml of WST-1 reagent
was added into each well. After 1 hour of incubation, the
absorbance at 450 nm was measured by a microplate reader
(Biorad, Hercules, CA). To assess the effect the microRNA on cell
proliferation, a WST-1 assay was performed in the 96-well format
at 72 hours after the microRNA/ncRNA transfection.
Cell cycle assay
Flow cytometric analysis of the DNA content was performed to
assess the effect of the microRNA on the cell cycle. Pn Day 0,
miR-26a/30b precursor or ncRNA oligo (final concentration:
25 nM) was transfected into SKBR3 or BT474 cells in a 6-well
Trastuzumab, miR-26a, and 30b in Breast Cancer
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After washing with PBS, the cells were treated with RNase A and
stained with propidium iodide (PI) using a Cellular DNA Flow
Cytometric Analysis kit (Roche Diagnostics, Basel, Switzerland).
The DNA content was evaluated using a FACS Calibur flow
cytometer (BD Biosciences, San Jose, CA) with Modfit LT
software (Verity Software House) for histogram analysis. Each
experiment was performed in triplicate.
Apoptosis assay
Annexin-V assays were performed for the detection of apoptotic
cells. After the transfection of the microRNA precursors on Day 0,
the cells were harvested on Day 3 and washed with PBS. The cells
were then stained using an Annexin V-FITC Apoptosis Detection
Kit I (BD Biosciences). The untreated cells served as a negative
control for the double staining. The cells were analyzed
immediately after staining using FACS Calibur flow cytometer
and Cell Quest Pro software.
Luciferase reporter assay for the association between the
39UTR of target gene candidates and miR-30b
First, an EcoRI site was introduced into the XbaI site of the
luciferase reporter vector pGL4.13 (Proamega, Madison, WI,
USA) by ligation with the oligonucleotides 59-CTAGACT-
GAATTC-39 and 59-CTAGGAATTCAGT-39, yielding the
pGL4.13EcoRI vector [13]. Second, the 39-untranslated regions
(UTRs) of the CCNE2, cyclin A1 (CCNA1), and cell division cycle 7
(CDC7) genes were amplified fromBT474 cells using the PCR
primers listed in Table S2, and cloned into a pCR4-TOPO vector
(Invitrogen). The cloned EcoRI fragments containing the putative
miR-30b binding sites were then inserted into the EcoRI site of
pGL4.13EcoRI, and were designated CCNE2-wt, CCNA1-wt,
and CDC7-wt, respectively. Three derivative constructs o
CCNE2-wt with mutations in the putative miR-30b-binding sites
were generated using a Gene-Taylor Mutagenesis kit (Invitrogen)
and the primers listed in Table S2, and were designated CCNE2-
mut1, -mut2, and –mut1+2. All of the constructs were verified by
direct sequencing. MicroRNA oligos or ncRNA were co-
transfected with 200 ng each of the constructed reporter vector
constructs and an internal control vector (pGL4.73, Promega) into
HEK293 cells (5610
4 cells) in a 24-well format. Twenty-four
hours later, the luciferase activity was measured using a dual-
luciferase reporter assay system (Promega) and a Lumat LB9507
luminometer (Berthold Technologies, Germany). The firefly
luciferase activities of the reporter constructs were normalized
against the renilla luciferase activities of the internal control vector,
The reduction ratio of the luciferase activity from the ncRNA-
transfected samples was used as an index of the effect of the
microRNAs on the post-transcriptional regulation of these 3 genes.
Statistical analysis
The unpaired student-t test was used for evaluating whether a
difference between two mean values was statistically significant.
Matlab 2011a (Mathworks, MA, USA) or Microsoft Excel (Micro-
soft, Redmond, WA) software was used for these analyses, and a P-
value of less than 0.05 was considered statistically significant.
Results
HER2 status and trastuzumab sensitivity in breast cancer
cell lines
To select HER2-positive and negative breast cancer cell lines,
we determined the HER2 status of the breast cancer cells in terms
of genomic amplification and the mRNA expression of HER2.
Figure 1A and 1B show the genome copy number in the HER2
locus and the mRNA expression levels of HER2 gene assessed by
quantitative PCR, respectively. Among the 11 breast cancer cells,
SKBR3 andBT474 exhibited marked genomic amplification and
the overexpression of HER2, and MDA-MB-453 had a moderate
level of HER2 overexpression. Thus, for further study, we chose
SKBR3 and BT474 as HER2-positive cells and MCF7 and MDA-
MB-231 as HER2-negative cells.
The WST-1 assays showed that even very low concentrations of
trastuzumab significantly reduced cell proliferation in SKBR3
andBT474 cells by 40–60%, whereas the proliferation of MCF7
and MDA-MB-231 cells was not affected by trastuzumab exposure
(Fig. 1C). Thus, trastuzumab exposure directly reduced the growth
of HER2-positive cells.
Identification of trastuzumab-responsive microRNAs
In this study, we hypothesized that some of the trastuzumab-
inducible/reducible microRNAs would play roles in the molecular
mechanisms responsible for the therapeutic effect of trastuzumab.
To identify these microRNAs, we performed microRNA expres-
sion profiling analysis. First, the two HER2-positive and two
HER2-negative breast cancer cell lines were exposed to trastuzu-
mab at a concentration of 4 mg/mL for six days. The control
treatment consisted of PBS. Thus, a total of 8 RNA samples were
extracted from these cells, and were subjected to microRNA
profiling analysis. Second, the obtained microRNA profiling data
were normalized by a quantile normalization method, and filtered
using the criterion that the microRNA signals before or after
trastuzumab exposure for each of the four cells, SKBR3, BT474,
MCF7, and MDA-MB-231 cells, should be more than 6 in log2
transformed value. After this filtration, 94 microRNAs were
subjected to further screening. All normalized and raw data from
the microarray is available in Minimum Information about
Microarray Gene Experiment (MIAME)-compliant format via
the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo). The accession numbers (GSM-numbers) are currently in the
registration process. Third, the expression of trastuzumab-
responsive microRNAs should not be changed by trastuzumab
exposure in HER2-negative breast cancer cell lines MCF7 and
MDA-MB-231. We eliminated those microRNAs, which had a
more than 1.5-fold up/down-regulation in the MCF7 or MDA-
MB-231 cells. Thus, 71 microRNAs remained. Fourth, the relative
fold-change (fold change of microRNAs – average fold change of
the microRNAs in MCF7 and MBA-MD-231 cells) of the
remaining microRNAs, and microRNAs with more than a 1.5-
fold up/down-regulation, were listed in Table 1.
Trastuzumab exposure upregulated 16 and 9 microRNAs in
SKBR3 and BT474 cells, whereas it down-regulated 0 and 10
microRNAs, respectively. As shown in a clustergram of 94
prefiltered microRNAs (Figure 2A), all pairs of the same cells
with versus without trastuzumab treatment were clustered most
closely, which indicated that the trastuzumab treatment changed
microRNA profile slightly. The first branch of the clustergram
divided HER2-positive and HER2-negative cells. This clustergram
shows that the microRNA profile was reflected by the HER2-
characteristics ofSKBR3, BT474, MCF7, and MDA-MB-231
cells, indicating that this profiling analysis worked well. The height
of the last branch in the clustergram for the HER2-positive cells
was higher than that of the HER2-negative cells, indicating that
the HER2-positive cells had more altered microRNA expression
than the HER2-negative cells. A heatmap and the clustergram in
Figure 2B illustrated the fold-change pattern of the four cells
following trastuzumab treatment.
Trastuzumab, miR-26a, and 30b in Breast Cancer
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31422Among the listed microRNAs, we selected seven microRNAs
(miR-18a, miR-21, miR-26a, miR-26b, miR-30b, miR98 and
miR-210) to validate the array-based expression data by Taqman
quantitative RT-PCR (Figure 2C, 2D, S1). Most of the
microRNAs showed consistent results with the array data. In
particular, miR-26a and miR-30b in both cells were significantly
upregulated in trastuzumab dose-dependent manner (Figure 2E).
Interestingly, 3 out of 5 miR-30 family members (miR-30a,e)
were upregulated in the BT474 cells following trastuzumab
exposure. Therefore, in this study, we focused on miR-26a and
miR-30b for a further functional study.
A list of microRNAs which expression were altered only in
HER2-negative cells is shown in Table S3. These microRNAs.
The changes in these microRNAs could help to identify non-
specific side effects of trastuzumab.
Cell growth suppressive effects of miR26a and miR-30b
Using WST-1 assay, we examined whether miR-26a and miR-
30b had growth suppressive effects. Six days after transfection,
miR-26a significantly reduced the proliferation ofSKBR3
andBT474 cells by 56% and 24%, whereas miR-30b inhibited
37% and 26% of the cell growth, respectively (Figure 3, p,0.05).
Next, we checked whether the mechanisms responsible for this
cell growth suppression by miR-26a and miR-30b included
changes in the cell cycle and apoptosis. The proportion of cells
in the G1 phase increased from 57% to 64% in theSKBR3 cells,
and from 65% to 91% in the BT474 cells (Figure 4, p,0.005), and
that in the S phase decreased from 37% to 31%, and from 29% to
6%, respectively. Thus, the trastuzumab treatment induced G1
arrest in both cell types. The transfection of miR-26a also showed
a 22% (p=0.14) and 11% (p=0.0002) increment of the G1
proportion, and a 20% (p=0.005) and 10% (p=0.0005)
decrement in the S phase in SKBR3 andBT474 cells, respectively.
In contrast, the G2/M phase had no significant changes in both
cell types. miR-30b also increased the G1 phase by 6% and 8%,
and decreased the S phase by 5% and 7%, respectively, whereas
the G2/M phase did not change. Thus, exogenous miR-26a and
miR-30b induced G1 arrest in SKBR3 and BT474 cells.
Figure 1. HER2-status of breast cancer cell lines. The genomic amplification (1A) and mRNA expression level (1B) of HER2 in 11 human breast
cancer cell lines and normal human mammary epithelial cells (HMEC) were assessed using quantitative PCR and quantitative RT-PCR (n=3). The
mRNA abundance was normalized by the GAPDH expression levels. 1C: The trastuzumab sensitivity of SKBR3, BT474, MCF7, and MDA-MB-231 cells
was determined using the WST-1 assay. The cells were incubated in trastuzumab-containing media at different concentrations for 144 hours, and
then the absorbance at 450 nm was measured after a 2-hour incubation with WST-1 reagent. The ratio of the absorbance to that of the non-treated
cells represented the trastuzumab sensitivity of cells.
doi:10.1371/journal.pone.0031422.g001
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apoptosis was involved in the cell growth suppression induced by
miR-26a and miR-30b. The trastuzumab treatment significantly
increased the portion of apoptotic cells from 8.1% to 14.7%
(Figure 5, p=0.012), and from 2.5% to 6.1% (p=0.003) inSKBR3
and BT474 cells, respectively. The transfection of miR-26a
induced apoptosis in both cell types, as compared with the non-
targeting control microRNA (from 11.3% to 39%, p=0.012 in
SKBR3, and from 4.7% to 15.2%, p=0.012 in BT474 cells),
whereas miR-30b did not show any significant effect on apoptosis.
Identification of target genes against miR-30b
In the present study, we tried to identify the target mRNAs of
miR-30b that were related to miR-30b-induced G1 arrest. First,
we utilized three different algorithms for predicting the microRNA
targets, TargetScan5.1 (http://www.targetscan.org/), miRanda
(http://www.microrna.org), and PicTar (http://www.pictar.org/).
Among the putative target genes listed by all of three prediction
engines, we selected 3 cell cycle-related genes, CCNE2, CCNA1,
and CDC7. We then examined whether these three genes were
actually regulated by miR-30b or not, using luciferase reporter
vectors containing the 39UTR of these genes (Figure 6A). CCNE2
and CDC7 have two and one putative binding sites for miR-30b in
the conserved regions of the 39-UTR, respectively, whereas
CCNA1 possesses one miR-30b binding site in a poorly conserved
region of the 39-UTR.
Among the three reporter constructs with the wild-type 39-UTR
of these genes, miR-30b reduced the luciferase activity only of the
CCNE2-wt construct (27% reduction, p=0.005, Figure 6B). To
confirm whether miR-30b was associated with the predicted
binding sites, we generated three derivative constructs with
mutations at the miR-30b binding sites (Figure 6A). These
mutations abolished the post-transcriptional repressive effect of
miR-30b (Figure 6C), which indicated that miR-30b interacts
directly with both binding sites. However, transfecting excessive
exogenous microRNA may lead an artificial effect. Thus, we tried
to assess suppressive effect of microRNAs at the endogenous level.
First, we used microRNA inhibitor for co-transfection (Figure S2),
which did not show any significant effect. We speculated that other
miR-30 family members with the same seed sequence could
compensate the function of blocked miR-30b. Alternatively, we
transfected reporter constructs without miR-30b mimic oligos into
cells (Figure 6D). Endogenous microRNAs suppressed 54–59% of
reporter actively by binding CCNE2. When mutated construct at
Table 1. Trastuzumab responsive microRNAs.
Rank microRNA RFC* in SKBR3 microRNA RFC* in BT474 microRNA Mean RFC*
Up-regulated microRNAs
1 miR-663 2.6847 miR-1246 3.5825 miR-1246 2.9505
2 miR-1228-5p 2.5757 miR-26a 2.3305 miR-26a 2.1640
3 miR-1246 2.4300 miR-125a-5p 1.7146 miR-1228-5p 2.0419
4 miR-21 2.2558 miR-23a 1.6897 miR-663 1.9317
5 miR-26b 2.0749 miR-30c 1.6455 miR-125a-5p 1.6925
6 miR-98 2.0446 miR-1228-5p 1.6187 miR-1908 1.6487
7 miR-26a 2.0093 miR-30b 1.6076 miR-23a 1.6303
8 miR-195 1.9996 miR-100 1.5625 miR-28-5p 1.6176
9 miR-28-5p 1.8877 miR-30d 1.5330 miR-26b 1.5799
10 miR-1908 1.8548 miR-100 1.5768
11 miR-29b 1.7555 miR-21 1.5335
















MicroRNAs with more than 1.5-fold change in HER2-positive cells but not in HER2-negative cells.
*: RFC, relative fold change=(Fold change of miR) – (average fold change of the miR in MCF7 and MBA-MD-231).
doi:10.1371/journal.pone.0031422.t001
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actively was recovered, which represented the total suppressive
effect of endogenous miR-30 family through CCNE2 39UTR.
Figure S3 showed that exogenous miR-30b mimic-oligos and
inhibitors did not change mRNA levels of CCNE2. One of possible
reasons is that miR-30b may regulate CCNE2 only by translational
inhibition. Another reason would be the change of cell cycle
proportion of treated cells. The CCNE2 is upregulated in G1 phase
of cell cycle in a normal condition. Because introduction of
miR26a/30b oligos increase G1 phase, CCNE2 expression will be
affected both by change of cell cycle phase proportion and post-
transcriptional suppression due to these microRNAs. Because the
two luciferase genes in reporter vector and internal control vector
(pGL4.73) were driven by the same promoter (SV40), this system
can assess the post-transcriptional regulation without any cell
cycle-related bias.
Discussion
Recent evidence has shown that altered patterns of miRNA
expression are correlated with carcinogenesis, malignant potential,
prognosis [14], and the treatment response of various human
cancers. In breast cancers, a high expression level of miR-10b [15]
and miR-21 [16] are associated with metastasis and a poor
outcome. Regarding the treatment response of breast cancer, the
in vitro experiments showed that miR-34a [17] and miR-221/222
[18,19] are involved in the actions of docetaxel and tamoxifen,
and that multidrug resistance–associated protein (MRP) was
targeted by miR-7, mir-326, and miR-345 [20,21]. However,
little has been reported in terms of microRNAs associated with the
molecular mechanisms of trastuzumab treatment. This was the
aim of this study.
At the beginning of this study, we confirmed the genome
amplification and mRNA expression status of HER2 among the
11 breast cancer cell lines. SKBR3 andBT474 cells have high
levels of genomic amplification and mRNA expression, and also
exhibited trastuzumab sensitivity. This finding was also consistent
with previous studies [22,23].
To screen the microRNAs related to the mechanisms of
trastuzumab treatment, we initially set two selection criteria.
The first one was microRNAs that were differentially expressed
between trastuzumab sensitive and resistant HER2-positive breast
cancer cells, and the second was microRNAs that were induced or
reduced by trastuzumab treatment only in HER2-positive cells.
For the former criterion, all of the HER2-positive breast cancer
cells were trastuzumab sensitive. Furthermore, to establish
trastuzumab-resistant HER2-positive cells, we administered tras-
tuzumab to SKBR3 andBT474 cells at a concentration of 32 mg/
mL for more than three months. However, these long-treated cells
gained only 10–20% resistance as compared to the original cells,
which were still moderately sensitive, similar to the MDA-MB-453
cells (data not shown). This was the reason why we chose the latter
criteria in this study.
Using microarray-based microRNA profiling analysis and these
screening criteria, we obtained a list of trastuzumab responsive
microRNAs, as shown in Table 1. The validation of the RT-PCR
demonstrated that most of the seven microRNAs had expression
results consistent with the microarray data. Among the seven
Figure 2. Identification of trastuzumab-responsive microRNAs. 2A: A heat map and clustergram of the expression profile of 71 pre-filtered
microRNAs. The red and green represent higher and lower expression levels, respectively. (tras +): with trastuzumab treatment, (tras 2): without
trastuzumab treatment. 2B: A heatmap and clustergram of the fold-change of microRNA expression by trastuzumab treatment. The red and green
represent up- and down-regulation. 2C and 2D: The expression levels of miR-26a (2C) and miR-30b (2D) were validated by qRT-PCR (n=3). The data
are shown as microRNA expression levels relative to a control treatment (PBS). 2E: The expression level of miR-26a and miR-30b in different
trastuzumab concentrations was measured (n=2). The microRNA expression levels were normalized against miR-16. All bars and error bars represent
means 6 SEM. *: p,0.05.
doi:10.1371/journal.pone.0031422.g002
Figure 3. Effects of miR-26a and miR-30b on cell proliferation. The cells were transfected with negative control RNA (ncRNA), miR-26a, or
miR-30b. At 72 hours after the transfection, the amount of viable cells was assessed by the WST-1 assay. The WST-1 activity values were normalized
against that of the ncRNA-treatment. All bars and error bars represent means 6 SEM (n=4). *: p,0.05.
doi:10.1371/journal.pone.0031422.g003
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in bothSKBR3 andBT474 cells, and on miR-30b, because three
out of five miR-30 family members were up-regulated inBT474
cells.
A down-regulation of miR-26a has been observed in various
human malignancies, such as thyroid [24], liver cancer [25] and
rhabdomyosarcoma [26], indicating that miR-26a is a tumor-
suppressor microRNA. This study showed that the up-regulation
of miR-26a by trastuzumab induced G1 arrest and apoptosis,
which was consistent with previous observations. Some papers
have reported the genes that were targeted by miR-26a, and are
related to cell cycle and apoptosis. miR-26a regulated the cell cycle
by targeting cyclin D2 and CCNE2 [27], and induced apoptosis by
silencing the enhancer of zeste, drosophila, homolog 2 (EZH2), and
metadherin (MTDH) [28].
The expression of miR-30b was suppressed in invasive bladder
cancer [29] and lung squamous cell carcinoma [30], as compared
with superficial bladder cancer and the adjacent normal lung
tissues, respectively. This suggests that miR-30b is also a tumor-
suppressor microRNA. Transfecting with miR-30b had a cell
growth suppressive effect and induced G1 cell cycle arrest, which
was in agreement with the previous reports. Although information
regarding the target genes of miR-26a was available, little has been
known in terms of miR-30 target. Therefore, we screened the
target genes of miR-30b that contributed to the miR-30b-induced
G1 arrest. In this study, we demonstrated that miR-30b interacts
directly with two binding sites in the 39-UTR of CCNE2, and
suppresses the expression of CCNE2. Cyclin E as well as Cyclins A
and D are required for mammalian cells to transverse G1 and
enter the S phase. Cyclin E1 and E2 activate cyclin-dependent
kinase 2 (CDK2) by forming a CCNE-CDK2 complex [31], and
initiate DNA synthesis. Therefore, it was a reasonable finding that
the downregulation of CCNE2 by miR-30b induced G1 arrest. In
Table 1, miR-30c and miR-30d were up-regulated by trastuzumab
in BT474 cells. These miR-30 family members share the same
sequence, 59-GUAAACA-39, in their seed regions. Thus, CCNE2
would be reduced in trastuzumab-treated BT474 cells not only by
an up-regulation of miR-30b and miR-26a, but also by that of
miR-30c/d. Recently, Scaltriti et al. demonstrated that gene
amplification and overexpression of CCNE1 were associated with
resistance of trastuzumab treatment for breast cancer [32],
suggesting that cell cycle check-point system by CCNE is a key
function for HER2-positive breast cancer. Thus, our finding that
trastuzumab-inducible miR-26a/30b are regulating CCNE2 was
consistent with the their finding.
As shown in table 1, miR-125a-5p level was up-regulated both
in SKBR3 and BT474 cells by trastuzumab exposure. Nishida et
Figure 5. Effects of miR-26a and miR-30b on apoptosis. The
apoptotic cells were detected using FITC-Annexin V at 72 hours after
microRNA transfection. The percentage of Annexin V-FITC positive cells
to the total cells was shown in the bar graphs. All bars and error bars
represent means 6 SEM (n=4). *: p,0.05, **: p,0.005.
doi:10.1371/journal.pone.0031422.g005
Figure 4. Effects of miR-26a and miR-30b on the cell cycle. The PI-stained DNA content of the cells was evaluated using a FACS Calibur (BD
Biosciences) at 72 hours after transfection. All bars and error bars represent means 6 SEM (n=6). *: p,0.05, **: p,0.005.
doi:10.1371/journal.pone.0031422.g004
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acts synergistically with trastuzumab in gastric cancer [33]. Our
result suggested that the same mechanism would underlie
trastuzumab therapy for breast cancer.
However, generally, each microRNA can target potentially
hundreds of genes. Therefore, the cell cycle/apoptosis may not be
the only processes affected/regulated by miR-26a/miR-30b. In
addition, this study is not suggesting that the suppressive effect in
endogenous level of these microRNA is a main mechanism of
trastuzumab therapeutic effect. Direct blocking effect of HER2
signal pathway is still the major mechanism of trastuzumab
therapy, and alteration of microRNA expression could play a
supporting role in the downstream of HER2 signal.
On the other hand, it is largely unknown how miR-26a and
miR-30b are up-regulated by trastuzumab treatment. One
possible explanation of this phenomenon is regulation via c-myc
(MYC) [34]. MYC is located downstream of the HER2 signal
pathway [35]. Thus, trastuzumab treatment can reduce the levels
of phospho-MYC [36]. According to the MYC ChIP-seq data
registered in the UCSC genome browser [37], there are c-myc
binding peaks around the transcriptional start sites of the miR-26a
primary genes (CTDSPL in chromosome 3p22.2 and CTDSP2 in
12q14.1). Actually, a report showed that miR-26a was repressed
by MYC [38]. Furthermore, there is a MYC-binding site in a CpG
island located upstream of the intergenic and polycistronic miR-
30b and miR-30d. Thus, we hypothesized that inactivation of
MYC may upregulate miR-30b/d expression. However, knock
down of MYC by siRNA down regulated miR-30b expression
(Figure S4 and S5). Therefore, unknown mechanisms rather than
MYC upregulate miR-30b expression in trastuzumab treatment.
The present study demonstrated that a subset of microRNAs
played a biological role in the mechanisms responsible for
trastuzumab’s antitumor effects. This finding suggests that
trastuzumab-resistant HER2-positive breast cancer cells could be
sensitized to trastuzumab therapy by modulating the expression of
these microRNAs [39]. Alternatively, some microRNAs would be
biomarkers to predict the treatment response of trastuzumab.
In summary, trastuzumab treatment for breast cancer cells
modulated the expression of a subset of microRNAs, including
miR-26a and miR-30b. The up-regulation of miR-30b by
trastuzumab may play a biological role in trastuzumab-induced
cell growth inhibition by targeting CCNE2.
Figure 6. CCNE2 is a direct target of miR-30b in breast cancer cells. 6A: A diagram of the 39UTR-containing reporter constructs for CCNE2,
CCNA1, and CDC7 and their derivatives. The 39UTRs of the three genes were inserted just downstream of the firefly luciferase gene in the pGL4.13
vector (wt). Next, the mutated derivatives (mut1, mut2, and mut1+2) of CCNE2-wt were generated by inserting mutations into two putative binding
sites corresponding to the seed-sequence of miR-30b. 6B and 6C: SKBR3 and BT474 cells were co-transfected with reporter constructs, internal control
vector (pGL4.73), and synthetic miR-30b oligomer. 6D: assessment of endogenous microRNA’s inhibitory effects to CCNE2. Only reporter constructs
and pGL4.73 were transfected into SKBR3 and BT474 cells. Twenty-four hours after the transfection, the reporter luciferase activity was measured. The
data were shown as the luciferase activity relative to that of vehicle (pGL4.13+pGL4.73) transfection. All bars and error bars represent means 6 SEM
(n=3). *: p,0.05, **: p,0.005.
doi:10.1371/journal.pone.0031422.g006
Trastuzumab, miR-26a, and 30b in Breast Cancer
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31422Supporting Information
Figure S1 Taqman RT-PCR to validate the microarray
results. The fold change in the log2 values are shown in the Y-
axis.
(TIFF)
Figure S2 Effect of microRNA inhibitors on the CCNE2-
39UTR reporter assay. SKBR3 cells were transfected with
CCNE2-wt construct and microRNA inhibitors to assess the
suppressive effect of endogenous microRNAs. Twenty-four hours
after the transfection, the reporter luciferase activity was
measured. NTC: non-specific control oligos. The data were
shown as the luciferase activity relative to that of NC. All bars and
error bars represent means 6 SEM (n=3). *: p,0.05, **:
p,0.005.
(TIFF)
Figure S3 Effect of knockdown and overexpression of
miR-26a and 30b on CCNE2 mRNA expression. SKBR3
and BT474 cells were transfected with microRNA mimic oligos
and inhibitors. Twenty-four hours after the transfection, mRNA
level of CCNE2 was measured by quantitative RT-PCR. GAPDH
mRNA level was used for normalization of data. The data using
inhibitor and mimic oligo were shown as relative expression to
each non-specific control (NC) oligo. All bars and error bars
represent means 6 SEM (n=4).
(TIFF)
Figure S4 Knocking down efficiency of MYC by siRNA.
MYC mRNA level was measured by quantitative RT-PCR after
72 hours later than control siRNAs (siCont) or 4 different siRNAs
(Qiagen) against MYC gene that were purchased from Qiagen,
designated as siMYC1, siMYC5, siMYC7, and siMYC8. The
siMYC5 and siMYC7 were selected for further study. Y-axis: MYC
expression level relative to siCont transfection. All bars and error
bars represent means 6 SEM (n=3).
(TIFF)
Figure S5 Effect of MYC knockdown on miR26a and
miR30b expression. The microRNA (miR26a and 30b)
expression level was measured by Taqman RT-PCR system after
72 hours later than the transfection of siCont or siMYCs. Y-axis:
microRNA expression level relative to that of siCont transfection.
All bars and error bars represent means 6 SEM (n=3).
(TIFF)
Table S1 Primer sequences for quantitative PCR.
(DOCX)
Table S2 Primer sequences for generating luciferase
reporter constructs.
(DOCX)
Table S3 Trastuzumab responsive microRNAs in
HER2-negative cells. MicroRNAs with more than 1.5-fold
change in HER2-negative cells but not in HER2-positive cells. *:
RFC, relative fold change=(Fold change of miR) – (average fold
change of the miR in SKBR3 and BT474)
(DOCX)
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